Skip to main content

Table 3 Correlations of changes between first two visits (Δ = first visit – second visit) in levels of BAFF or anti-Jo-1 antibodies with change of disease activity and their association with prior daily dose of glucocorticoids given at initial assessment

From: Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis

  Change in BAFF Change in anti-Jo-1 GC daily dose
n r p n r p n r p
Δ BAFF 44 0.18 0.25 43 0.31 0.04a
Δ CK 44 0.75 < 0.0001*** 42 0.24 0.13 41 0.23 0.14
Δ Myoglobin 36 0.64 < 0.0001*** 34 0.44 0.009 33 0.35 0.04
Δ ALT 45 0.52 0.0003** 43 0.31 0.04 42 0.33 0.03
Δ AST 43 0.63 < 0.0001*** 41 0.54 0.0003** 40 0.30 0.05
Δ CRP 42 0.32 0.04 40 0.33 0.04 39 0.27 0.10
Δ Muscle VAS 39 0.33 0.04 37 −0.12 0.49 39 0.28 0.08
Δ Global VAS 39 0.38 0.02 37 −0.05 0.78 39 0.38 0.02
Δ Skeletal VAS 39 0.45 0.004** 37 0.1 0.56 39 0.06 0.72
Δ Cutaneous VASb 12 0.64 0.03a 11 −0.03 0.92 12 0.38 0.22
Δ Pulmonary VASc 30 −0.01 0.94 28 −0.30 0.12 30 0.42 0.02a
  1. ALT alanine aminotransferase, AST aspartate aminotransferase, BAFF B-cell activating factor of the tumour necrosis factor family, CK creatine kinase, CRP C-reactive protein, GC glucocorticoids, VAS visual analogue scale
  2. p = p value; **alfa = 0.01 (0.001 after Bonferroni correction); ***alfa = 0.001 (0.0001 after Bonferroni correction).
  3. aNo multiple testing correction applicable
  4. bEvaluated within patients with dermatomyositis
  5. cEvaluated within patients with interstitial lung disease